Yes, people have undergone CAR T-cell therapy and bispecific T-cell engager (BiTE) treatments for multiple myeloma. Here are some details:

CAR T-Cell Therapy
- Abecma (idecabtagene vicleucel): This is an approved CAR T-cell treatment for multiple myeloma. It is designed for people whose myeloma is refractory (resistant read more

Yes, people have undergone CAR T-cell therapy and bispecific T-cell engager (BiTE) treatments for multiple myeloma. Here are some details:

CAR T-Cell Therapy:
- Abecma (idecabtagene vicleucel): This is an approved CAR T-cell treatment for multiple myeloma. It is designed for people whose myeloma is refractory (resistant to treatment) or relapsed (came back after being treated) and who have tried at least four other treatments.
- Process: T cells are collected from the patient, genetically modified to recognize and kill cancer cells, and then infused back into the patient.
- Response: Studies show that 28% of people achieved a complete response, with 65% maintaining the response for at least 12 months.

Bispecific T-Cell Engagers (BiTEs):
- Teclistamab-Cqyv: This is a new treatment for relapsed or refractory multiple myeloma (RRMM). BiTEs use monoclonal antibodies to help the body recognize and remove cancerous cells.

Clinical Outcomes:
- Carvykti: Another anti-BCMA CAR T-cell therapy, showed an overall response rate of 98% in clinical trials, with a median duration of response of 22 months.

These treatments are promising but can be difficult to access and may have serious side effects. Always consult with a healthcare provider for personalized advice.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

CAR-T Cell Therapy for Multiple Myeloma: What Is It? | MyMyelomaTeam

What Is BCMA-Targeted Immunotherapy for Multiple Myeloma? | MyMyelomaTeam